Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
28 Abril 2022 - 9:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
non-alcoholic steatohepatitis (NASH), will report its first quarter
2022 financial results on Monday, May 9, 2022 and provide business
and clinical program updates with some additional results from the
Phase 3 MAESTRO-NAFLD-1 study.
The schedule for the press release and conference call/webcast
is as follows:
Press Release: |
May 9th, 2022 at 6:30 am ET |
Conference Call: |
May 9th, 2022 at 8:00 am ET |
• Domestic Dial-In Number: |
(833) 660-2754 |
• International Dial-In Number: |
(409) 350-3497 |
• Conference ID Number: |
9765409 |
To access the live webcast of the call please visit the Investor
Events and Presentations section of Madrigal’s website or click
here. An archived webcast will be available on the Madrigal website
after the event.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
non-alcoholic steatohepatitis (NASH), a liver disease with high
unmet medical need. Madrigal’s lead candidate, resmetirom, is a
once daily, oral, thyroid hormone receptor (THR)-β selective
agonist that is designed to target key underlying causes of NASH in
the liver. Resmetirom is currently being evaluated in two Phase 3
clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to
demonstrate multiple benefits in patients with NASH. For more
information, visit www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024